188 related articles for article (PubMed ID: 23697367)
21. The role of microRNAs in ovarian cancer.
Kinose Y; Sawada K; Nakamura K; Kimura T
Biomed Res Int; 2014; 2014():249393. PubMed ID: 25295252
[TBL] [Abstract][Full Text] [Related]
22. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
23. Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.
Liu L; Zou J; Wang Q; Yin FQ; Zhang W; Li L
Tumour Biol; 2014 Aug; 35(8):7713-7. PubMed ID: 24805828
[TBL] [Abstract][Full Text] [Related]
24. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
Zheng H; Zhang L; Zhao Y; Yang D; Song F; Wen Y; Hao Q; Hu Z; Zhang W; Chen K
PLoS One; 2013; 8(11):e77853. PubMed ID: 24223734
[TBL] [Abstract][Full Text] [Related]
25. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.
Zou D; Wang D; Li R; Tang Y; Yuan L; Long X; Zhou Q
Tumour Biol; 2015 Sep; 36(9):6725-32. PubMed ID: 25833695
[TBL] [Abstract][Full Text] [Related]
26. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Beaufort CM; Helmijr JC; Piskorz AM; Hoogstraat M; Ruigrok-Ritstier K; Besselink N; Murtaza M; van IJcken WF; Heine AA; Smid M; Koudijs MJ; Brenton JD; Berns EM; Helleman J
PLoS One; 2014; 9(9):e103988. PubMed ID: 25230021
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1.
Jin M; Yang Z; Ye W; Xu H; Hua X
PLoS One; 2014; 9(8):e103965. PubMed ID: 25090005
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.
Chen XP; Chen YG; Lan JY; Shen ZJ
Cancer Lett; 2014 Oct; 353(2):201-10. PubMed ID: 25063739
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
Koutsaki M; Spandidos DA; Zaravinos A
Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
[TBL] [Abstract][Full Text] [Related]
30. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
31. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
Kim YW; Kim EY; Jeon D; Liu JL; Kim HS; Choi JW; Ahn WS
Drug Des Devel Ther; 2014; 8():293-314. PubMed ID: 24591819
[TBL] [Abstract][Full Text] [Related]
32. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes.
Shapira I; Oswald M; Lovecchio J; Khalili H; Menzin A; Whyte J; Dos Santos L; Liang S; Bhuiya T; Keogh M; Mason C; Sultan K; Budman D; Gregersen PK; Lee AT
Br J Cancer; 2014 Feb; 110(4):976-83. PubMed ID: 24366298
[TBL] [Abstract][Full Text] [Related]
33. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
34. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
Yu PN; Yan MD; Lai HC; Huang RL; Chou YC; Lin WC; Yeh LT; Lin YW
Int J Cancer; 2014 Feb; 134(3):542-51. PubMed ID: 23904094
[TBL] [Abstract][Full Text] [Related]
36. MicroRNAs as therapeutic targets in chemoresistance.
Garofalo M; Croce CM
Drug Resist Updat; 2013; 16(3-5):47-59. PubMed ID: 23757365
[TBL] [Abstract][Full Text] [Related]
37. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.
Hadla M; Palazzolo S; Corona G; Caligiuri I; Canzonieri V; Toffoli G; Rizzolio F
Nanomedicine (Lond); 2016 Sep; 11(18):2431-41. PubMed ID: 27558906
[TBL] [Abstract][Full Text] [Related]
38. Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.
Pathak A; Pal AK; Roy S; Nandave M; Jain K
Stem Cells Int; 2024; 2024():9077926. PubMed ID: 38213742
[TBL] [Abstract][Full Text] [Related]
39.
Yang M; Gao X; Hu C; Wang S; Sheng H; Ma Y
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628891
[TBL] [Abstract][Full Text] [Related]
40. Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
Lopacinska-Jørgensen J; Petersen PHD; Oliveira DVNP; Høgdall CK; Høgdall EV
PLoS One; 2023; 18(5):e0282576. PubMed ID: 37141239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
